-
Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
Julia Marie Unglaub, Richard F. Schlenk, Maher Hanoun, Hans Christian Reinhardt, Jan Moritz Middeke, Kerstin Schäfer‐Eckart, +30 more
0citations -
Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
Inga Hund, Maria Elena Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, +13 more
0citations -
Analysis of the Impact of Body Mass Index (BMI) on the Durability of Response in Patients with Aplastic Anemia Treated with Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG)
Jeanette Walter, Benjamin Rolles, Frauke Theis, Leo Hansmann, Daniel Heudobler, Markus Philipp Radsak, +10 more
0citations -
Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis2023 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, Jun‐ichi Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
0citations -
CSF3RT618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)2024 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Endoplasmic Reticulum Stress and Disease
Alessandra Hartke, Axel Künstner, Anke Fähnrich, Hauke S. Busch, Timo Gemoll, Jasmin Osius, +10 more
0citations -
Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)
Lukas Peter Frenzel, Laura Beckmann, Sandra Robrecht, Anna Maria Fink, Othman Al‐Sawaf, Christof Schneider, +9 more
0citations -
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Phillip Scheinberg, Diego V. Clé, Bérangère Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan‐Yu Lin, +12 more
0citations -
Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
Susanne Isfort, Kirsi Marjaana Manz, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +18 more
0citations -
Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies - a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
Tim Lohmann, Matthias Stelljes, Caroline Pabst, Stefan Klein, Johanna Tischer, Alessia Fraccaroli, +13 more
0citations -
Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner Drouet, Lutz Peter Mueller, Christoph Schmid, +30 more
0citations -
New Criteria for Evaluating Outcomes of Myelofibrosis Therapy2024 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Monia Marchetti, Alessandro Maria Vannucchi, John O Mascarenhas, Alberto Álvarez‐Larrán, Prithviraj Bose, Robert Peter Gale, +9 more
0citations -
ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options
Jean‐Jacques Kiladjian, Francisca Ferrer‐Marín, Haifa Kathrin Al‐Ali, Alberto Álvarez‐Larrán, Eloise Beggiato, Maria Bieniaszewska, +35 more
0citations -
The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate2024 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Blood disorders and treatments
Jeanette Walter, Benjamin Rolles, Frauke Theis, Leo Hansmann, Markus Philipp Radsak, Michael Heuser, +12 more
0citations